Lilly's new combination therapy outperforms tirzepatide in late-stage obesity trial

Eli Lilly advances its obesity treatment pipeline with promising Phase 2b results for a novel drug combo that surpasses existing therapies in weight loss and metabolic improvements, setting the stage for future Phase 3 trials. Eli Lilly has strengthened its…















